BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 29618692)

  • 21. Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis.
    Schlenk RF; Stegelmann F; Reiter A; Jost E; Gattermann N; Hebart H; Waller C; Hochhaus A; Platzbecker U; Schafhausen P; Blau IW; Verbeek W; Heidel FH; Werner M; Kreipe H; Teleanu V; Benner A; Döhner H; Grießhammer M; Döhner K
    Leukemia; 2017 Apr; 31(4):889-895. PubMed ID: 27774990
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Comparison of low-dose thalidomide and prednisone combined with or without danazol for the treatment of primary myelofibrosis-associated anemia].
    Xu J; Xu Z; Qin T; Li B; Fang L; Zhang H; Hu N; Pan L; Qu S; Zhang Y; Xiao Z
    Zhonghua Xue Ye Xue Za Zhi; 2014 Aug; 35(8):698-702. PubMed ID: 25152115
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia.
    Merup M; Kutti J; Birgergård G; Mauritzson N; Björkholm M; Markevärn B; Maim C; Westin J; Palmblad J;
    Med Oncol; 2002; 19(2):79-86. PubMed ID: 12180484
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Struggling with myelofibrosis-associated anemia.
    Guglielmelli P; Vannucchi AM
    Leuk Res; 2013 Nov; 37(11):1429-31. PubMed ID: 24011697
    [No Abstract]   [Full Text] [Related]  

  • 25. Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results.
    Cervantes F; Isola IM; Alvarez-Larrán A; Hernández-Boluda JC; Correa JG; Pereira A
    Ann Hematol; 2015 Nov; 94(11):1791-6. PubMed ID: 26122869
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hairy cell leukemia (HCL) with extensive myelofibrosis responds to thalidomide.
    Strupp C; Fenk R; Kündgen A; Gattermann N; Haas R; Germing U
    Leuk Res; 2005 Aug; 29(8):967-9. PubMed ID: 15978949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Review of evidence of thalidomide and lenalidomide in different hematological diseases: chronic lymphocytic leukemia, primary amyloidosis, myelofibrosis and syndrome myelodysplastic].
    Jiménez Lozano I; Juárez Jiménez JC
    Farm Hosp; 2013; 37(4):322-34. PubMed ID: 24010694
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Two cases of myelofibrosis with severe thrombocytopenia and symptomatology successfully treated with combination of pomalidomide and ruxolitinib.
    Andrei M; Sindhu H; Wang JC
    Leuk Lymphoma; 2015 Feb; 56(2):524-6. PubMed ID: 24893800
    [No Abstract]   [Full Text] [Related]  

  • 29. Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.
    Offidani M; Corvatta L; Caraffa P; Leoni P; Pautasso C; Larocca A; Palumbo A
    Expert Rev Anticancer Ther; 2014 May; 14(5):499-510. PubMed ID: 24738833
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunomodulatory agents in myelofibrosis.
    Tabarroki A; Tiu RV
    Expert Opin Investig Drugs; 2012 Aug; 21(8):1141-54. PubMed ID: 22668122
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Momelotinib: an emerging treatment for myelofibrosis patients with anemia.
    Chifotides HT; Bose P; Verstovsek S
    J Hematol Oncol; 2022 Jan; 15(1):7. PubMed ID: 35045875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thalidomide for the treatment of idiopathic myelofibrosis.
    Strupp C; Germing U; Scherer A; Kündgen A; Mödder U; Gattermann N; Haas R
    Eur J Haematol; 2004 Jan; 72(1):52-7. PubMed ID: 14962263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Toxic epidermal necrolysis in a patient with primary myelofibrosis receiving thalidomide therapy.
    Colagrande M; Di Ianni M; Coletti G; Peris K; Fargnoli MC; Moretti L; Lapecorella M; Tabilio A
    Int J Hematol; 2009 Jan; 89(1):76-79. PubMed ID: 19052692
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thalidomide in agnogenic and secondary myelofibrosis.
    Canepa L; Ballerini F; Varaldo R; Quintino S; Reni L; Clavio M; Miglino M; Pierri I; Gobbi M
    Br J Haematol; 2001 Nov; 115(2):313-5. PubMed ID: 11703326
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies.
    Barosi G; Elliott M; Canepa L; Ballerini F; Piccaluga PP; Visani G; Marchetti M; Pozzato G; Zorat F; Tefferi A
    Leuk Lymphoma; 2002 Dec; 43(12):2301-7. PubMed ID: 12613516
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia.
    Mesa RA; Steensma DP; Pardanani A; Li CY; Elliott M; Kaufmann SH; Wiseman G; Gray LA; Schroeder G; Reeder T; Zeldis JB; Tefferi A
    Blood; 2003 Apr; 101(7):2534-41. PubMed ID: 12517815
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of thalidomide and lenalidomide as therapy for myelofibrosis.
    Jabbour E; Thomas D; Kantarjian H; Zhou L; Pierce S; Cortes J; Verstovsek S
    Blood; 2011 Jul; 118(4):899-902. PubMed ID: 21622644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mini-dose of thalidomide for treatment of primary myelofibrosis. Report of a case with complete reversal of bone marrow fibrosis and splenomegaly.
    Berrebi A; Feldberg E; Spivak I; Shvidel L
    Haematologica; 2007 Feb; 92(2):e15-6. PubMed ID: 17405746
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pomalidomide.
    Engelhardt M; Wäsch R; Reinhardt H; Kleber M
    Recent Results Cancer Res; 2014; 201():359-72. PubMed ID: 24756804
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide.
    Chowdhury O; O'Sullivan J; Barkas N; Wang G; Buck G; Hamblin A; Tefferi A; Al-Ali HK; Barosi G; Devos T; Gisslinger H; Jiang Q; Kiladjian JJ; Mesa R; Passamonti F; Ribrag V; Schiller G; Vannucchi AM; Zhou D; McMullin MF; Zhong J; Gale RP; Mead AJ;
    Leukemia; 2021 Apr; 35(4):1197-1202. PubMed ID: 32770086
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.